Profil
NEIL Bajpayee served as a Board of Directors member at Actuate Therapeutics, Inc. from 2019 to 2020.
Prior to that, he worked as an Investment Associate at Kairos Venture Investments LLC from 2018 to 2020.
Bajpayee received his undergraduate degree from The Pennsylvania State University in 2004 and his doctorate degree from the University of California in 2011.
Anciens postes connus de NEIL Bajpayee
| Sociétés | Poste | Fin |
|---|---|---|
Kairos Venture Investments LLC
 Kairos Venture Investments LLC Investment ManagersFinance Kairos Venture Investments LLC (Kairos Venture) is a venture capital firm founded in 2015 by Jim Demetriades. The firm is headquartered in Beverly Hills, California. | Private Equity Investor | 30/10/2020 |
Actuate Therapeutics, Inc.
 Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Directeur/Membre du Conseil | 30/10/2020 |
Formation de NEIL Bajpayee
| The Pennsylvania State University | Undergraduate Degree |
| University of California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Kairos Venture Investments LLC
Kairos Venture Investments LLC Investment ManagersFinance Kairos Venture Investments LLC (Kairos Venture) is a venture capital firm founded in 2015 by Jim Demetriades. The firm is headquartered in Beverly Hills, California. | Finance |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Health Technology |
